1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: E33022, NCT00122746
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: E33024, NCT00122772
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: JCOG0505, C000000335, NCT00295789
|
|
5.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-002948-28, KKS-73-05, NCT00444093
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 006/027/ICI, NCT00532818
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10020380, NCT00770874
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0240, GOG-0240, NCT00803062
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 03-0298-C, NCT00188578
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ARCAGY-GINECO-CE102, GINECO CE102, ARCAGY-HYCAR, INCA-RECF0757, EUDRACT-2008-001842-19, NCT00807079
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-96205, NCI-V97-1356, NCT00003135
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CINJ-100101, NJ 1703, CINJ-3390, CINJ-NJ1703, NCT00138151
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCI 03-33, NCT00257816
|
|
14.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
15.
|
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UW-6143, UW IRB# 6143, 7958, NCT00559377
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-1098, GSK 107278, NCT00548418
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IOSI-RO0402, RO0402, NCT00637637
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2007-0324, NCT00626561
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.26, NCT00748709
|
|
20.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CACA-2008-GSK1, NCT00826891
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM104-B-001-09, NCT00900562
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: NCI
Protocol IDs: 090037, 09-C-0037, NCT00924066
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 08-0206-C, NCT00938106
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MITO CERV 2, EudraCT number: 2009-010099-74, NCT00997009
|
